Angiogenesis in hepatocellular carcinoma: A potential target for chemoprevention and therapy

Current Cancer Drug Targets

Volumn 12, Issue 9, 2012, Pages 1095-1118

  Bishayee, Anupam ^a,b   Darvesh, Altaf S ^a  

^a NORTHEAST OHIO MEDICAL UNIVERSITY   (United States)

^b Northeastern Ohio Medical University   (United States)

Author keywords

Angiogenesis; Anti angiogenic agents; Chemoprevention; Hepatocellular carcinoma; Treatment; Vascular endothelial growth factor

Indexed keywords

ADIPONECTIN; ALPHA INTERFERON; ANGIOPEPTIN; ANGIOSTATIN; BACITRACIN; BETA INTERFERON; BEVACIZUMAB; DOVITINIB; ENDOSTATIN; FARNOQUINONE; FINGOLIMOD; FLUOROURACIL; FORETINIB; FUMAGILLOL CHLOROACETYLCARBAMATE; HALOFUGINONE; HYPOXIA INDUCIBLE FACTOR; INTERLEUKIN 12; INTERLEUKIN 17F; INTERLEUKIN 24; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; OCTREOTIDE; PERINDOPRIL; PLACEBO; RAPAMYCIN; SORAFENIB; SUNITINIB; SURAMIN; THALIDOMIDE; TRIENTINE; UNINDEXED DRUG; VATALANIB;

ANEMIA; ANGIOGENESIS; ANTIANGIOGENIC ACTIVITY; APOPTOSIS; CELL PROLIFERATION; CHEMOPROPHYLAXIS; DIARRHEA; DIET THERAPY; DRUG SAFETY; FATIGUE; HUMAN; HYPERTENSION; IMMUNOHISTOCHEMISTRY; INSULIN RESISTANCE; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; METASTASIS; NEUTROPENIA; NONHUMAN; OVERALL SURVIVAL; OXIDATIVE STRESS; PERIPHERAL NEUROPATHY; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; REVIEW; TUMOR GROWTH; TUMOR VOLUME; VASCULARIZATION;

EID: 84872577704     PISSN: 15680096     EISSN: 18735576     Source Type: Journal    
DOI: 10.2174/156800912803987887     Document Type: Review

References (221)

1. Parkin, D. M.; Bray, F.; Ferlay, J.; Pisani, P. Global cancer statistics, 2002. CA Cancer J. Clin. 2005, 55, 74-108.
2. El-Serag, H. B.; Rudolph, K. L. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 2007, 132, 2557-2576.
3. Siegal, R.; Naishadham, D.; Jemal, A. Cancer statistics, 2012. CA Cancer J. Clin. 2012, 62, 10-29.
4. Davis, G. L.; Alter, M. J.; El-Serag, H.; Poynard, T.; Jennings, L. W. Aging of hepatitis C virus (HCV)-infected persons in the United States: a multiple cohort model of HCV prevalence and disease progression. Gastroenterology 2010, 138, 513-521.
5. Bartsch, H.; Montesano, R. Relevance of nitrosamines to human cancer. Carcinogenesis 1984, 5, 1381-1393.
6. Llovet, J. M.; Burroughs, A.; Bruix, J. Hepatocellular carcinoma. Lancet 2003, 362, 1907-1917.
7. Kensler, T. W.; Egner, P. A.; Wang, J. B.; Zhu, Y. R.; Zhang, B. C.; Lu, P. X.; Chen, J. G.; Qian, G. S.; Kuang, S. Y.; Jackson, P. E.; Gange, S. J.; Jacobson, L. P.; Muñoz, A.; Groopman, J. D. Chemoprevention of hepatocellular carcinoma in aflatoxin endemic areas. Gastroenterology 2004, 127, S310-318.
8. Schütte, K.; Bornschein, J.; Malfertheiner, P. Hepatocellular carcinoma-epidemiological trends and risk factors. Dig. Dis. 2009, 27, 80-92.
9. Bruix, J.; Sherman, M. Management of hepatocellular carcinoma. Hepatology 2005, 42, 1208-1236.
10. Lu S. C. Where are we in the chemoprevention of hepatocellular carcinoma? Hepatology 2010, 51, 734-736.
11. Thomas, M. B.; Jaffe, D.; Choti, M. M.; Belghiti, J.; Curley, S.; Fong, Y.; Gores, G.; Kerlan, R.; Merle, P.; O'Neil, B.; Poon, R.; Schwartz, L.; Tepper, J.; Yao, F.; Haller, D.; Mooney, M.; Venook A. Hepatocellular carcinoma: consensus recommendations of the National Cancer Institute Clinical Trials Planning Meeting. J. Clin. Oncol. 2010, 28, 3994-4005.
12. Morgan T. R. Chemoprevention of hepatocellular carcinoma in chronic hepatitis C. Recent Results Cancer Res. 2011, 188, 85-99.
13. Pang, R., Poon, R. T. P. Angiogenesis and antiangiogenic therapy in hepatocellular carcinoma. Cancer Lett. 2006, 242, 151-167.
14. Chen, J. A.; Shi, M.; Li, J. Q.; Qian, C. N. Angiogenesis: multiple masks in hepatocellular carcinoma and liver regeneration. Hepatol. Int. 2010, 4, 537-47.
15. Coulon, S.; Heindryckx, F.; Geerts, A.; Van Steenkiste, C.; Colle, I.; Van Vlierberghe, H. Angiogenesis in chronic liver disease and its complications. Liver Int. 2011, 31, 146-162.
16. Asahara, T.; Bauters, C.; Zheng, L. P.; Takeshita, S.; Bunting, S.; Ferrara, N.; Symes, J. F.; Isner, J. M. Synergistic effect of vascular endothelial growth factor and basic fibroblast growth factor on angiogenesis in vivo. Circulation 1995, 92, II365-371.
17. Sung, H. S.; Tang, Z. Y. Angiogenesis in hepatocellular carcinoma: the retrospectives and perspectives. J. Cancer Res. Clin. Oncol. 2004, 130, 307-319.
18. Tanaka, S.; Arii, S. Current status and perspective of antiangiogenic therapy for cancer: hepatocellular carcinoma. Int. J. Clin. Oncol. 2006, 11, 82-89.
19. Ribatti, D.; Vacca, A.; Nico, B.; Sansonno, D.; Dammacco, F. Angiogenesis and anti-angiogenesis in hepatocellular carcinoma. Cancer Treat. Rev. 2006, 32, 437-444.
20. Wu, X. Z. New strategy of antiangiogenic therapy for hepatocellular carcinoma. Neoplasma 2008, 6, 472-481.
21. Pircher, A.; Medinger, M.; Drevs, J. Liver cancer: targeted future options. World J. Hepatol. 2011, 27, 38-44.
22. Park, Y. N.; Kim, Y. B.; Yang, K. M.; Park, C. Increased expression of vascular endothelial growth factor and angiogenesis in the early stage of multistep hepatocarcinogenesis. Arch. Pathol. Lab. Med. 2000, 124, 1061-1065.
23. Bozova, S.; Elpek, G. O. Hypoxia-inducible factor-1alpha expression in experimental cirrhosis: correlation with vascular endothelial growth factor expression and angiogenesis. APMIS 2007, 115, 795-801.
24. Wang, W.; Xu, G.L.; Jia, W. D.; Wang, Z. H.; Li, J. S.; Ma, J. L.; Ge, Y. S.; Xie, S. X.; Yu, J. H. Expression and correlation of hypoxia-inducible factor-1alpha, vascular endothelial growth factor and microvessel density in experimental rat hepatocarcinogenesis. J. Int. Med. Res. 2009, 37, 417-425.
25. Bishayee, A.; Petit, D. M.; Samtani, K. Angioprevention is implicated in resveratrol chemoprevention of experimental hepatocarcinogenesis. J. Carcinog. Mutagen. 2010, 1, 102.
26. Tosetti, F.; Ferrari, N.; de Flora, S.; Albini, A. 'Angioprevention': angiogenesis is a common and key target for cancer chemopreventive agents. FASEB J. 2002, 16, 2-16.
27. Sun, H. C.; Tang, Z. Y.; Li, X.M.; Zhou, Y. N.; Sun, B. R.; Ma, Z. C. Microvessel density of hepatocellular carcinoma: its relationship with prognosis. J. Cancer Res. Clin. Oncol. 1999, 125, 419-426.
28. Sun, B.; Zhang, S.; Zhang, D.; Du, J.; Guo, H.; Zhao, X.; Zhang, W.; Hao, X. Vasculogenic mimicry is associated with high tumor grade, invasion and metastasis, and short survival in patients with hepatocellular carcinoma. Oncol. Rep. 2006, 16, 693-698.
29. Roskoski, R. Jr. VEGF receptor protein-kinases: structure and regulation. Biochem. Biophys Res. Commun. 2008, 375, 287-291.
30. Kaseb, A. O.; Hanbali, A.; Cotant, M.; Hassan, M. M.; Wollner, I.; Philip, P. A. Vascular endothelial growth factor in the management of hepatocellular carcinoma. Cancer 2009, 115, 4895-4906.
31. Sharma, P. S.; Sharma, R.; Tyagi, T. VEGF/VEGFR pathway inhibitors as anti-angiogenic agents. Curr. Cancer Drug Targets 2011, 11, 624-653.
32. Finn, R. S.; Zhu, A. X. Targeting angiogenesis in hepatocellular carcinoma: focus of VEGR and becacizumab. Expert. Rev. Anticancer Ther. 2009, 9, 503-509.
33. Van de Veire, S.; Stalmans, I.; Heindryckx, F.; Oura, H.; Tijeras-Raballand, A.; Schmidt, T.; Loges, S.; Albrecht, I.; Jonckx, B.; Vinckier, S.; Van Steenkiste, C.; Tugues, S.; Rolny, C.; De Mol, M.; Dettori, D.; Hainaud, P.; Coenegrachts, L.; Contreres, J. O.; Van Bergen, T.; Cuervo, H.; Xiao, W. H.; Le Henaff, C.; Buysschaert, I.; Kharabi Masouleh, B.; Geerts, A.; Schomber, T.; Bonnin, P.; Lambert, V.; Haustraete, J.; Zacchigna, S.; Rakic, J. M.; Jiménez, W.; Noël, A.; Giacca, M.; Colle, I.; Foidart, J. M.; Tobelem, G.; Morales-Ruiz, M.; Vilar, J.; Maxwell, P.; Vinores, S. A.; Carmeliet, G.; Dewerchin, M.; Claesson-Welsh, L.; Dupuy, E.; Van Vlierberghe, H.; Christofori, G.; Mazzone, M.; Detmar, M.; Collen, D.; Carmeliet, P. Further pharmacological and genetic evidence for the efficacy of PIGF inhibition in cancer and eye disease. Cell 2010, 141, 178-190.
34. 2 tension. Proc. Natl. Acad. Sci. USA 1995, 92, 5510-5514.
35. Salceda, S.; Caro, J. Hypoxia-inducible factor 1alpha (HIF-1alpha) protein is rapidly degraded by the ubiquitin-proteosome system under normoxic conditions. Its stabilization by hypoxia depends on redox-induced changes. J. Biol. Chem. 1997, 272, 22642-22647.
36. Harris, A. L. Hypoxia-a key regulator in angiogenesis. Nat. Rev. Cancer 2002, 2, 38-47.
37. Hirota, K.; Semenza, G. L. Regulation of angiogenesis by hypoxiainducible factor 1. Crit. Rev. Oncol. Hematol. 2006, 59, 15-26.
38. Kamura, T.; Sato, S.; Iwai, K.; Czyzyk-Krzeska, M.; Conaway, R. C.; Conaway, J. W. Activation of HIF1alpha ubiquitination by a reconstituted von Hippel-Lindau (VHL) tumor suppressor complex. Proc. Natl. Acad. Sci. USA 2000, 97, 10430-10435.
39. Sandau, K. B.; Zhou, J.; Kietzmann, T.; Brüne, B. Regulation of the hypoxia-inducible factor 1alpha by the inflammatory mediators nitric oxide and tumor necrosis factor-alpha in contrast to desferroxamine and phenylarsine oxide. J. Biol. Chem. 2001, 276, 39805-38911.
40. Yang, Z. F.; Poon, R. T.; To, J.; Ho, D. W.; Fan, S. T. The potential role of hypoxia inducible factor 1in tumor progression after hypoxia and chemotherapy in hepatocellular carcinoma. Cancer Res. 2004, 64, 5496-5503.
41. Huang, G.; Yang, L.; Lu, W. Expression of hypoxia-inducible factor 1and vascular endothelial growth factor in hepatocellular carcinoma: impact on neovascularization and survival. World J. Gastroenterol. 2005, 11, 1705-1708.
42. Pérez-Ruiz, M.; Ros, J.; Morales-Ruiz, M.; Navasa, M.; Colmenero, J.; Ruiz-del-Arbol, L.; Cejudo, P.; Clária, J.; Rivera, F.; Arroyo, V.; Rodés, J.; Jiménez, W. Vascular endothelial growth factor production in peritoneal macrophages of cirrhotic patients: regulation by cytokines and bacterial lipopolysaccharide. Hepatology 1999, 29, 1057-1063.
43. Akiba, J.; Yano, H.; Ogasawara, S.; Higaki, K.; Kojiro, M. Expression and function of interleukin-8 in human hepatocellular carcinoma. Int. J. Oncol. 2001, 18, 257-264.
44. Kubo, F.; Ueno, S.; Hiwatashi, K.; Sakoda, M.; Kawaida, K.; Nuruki, K.; Aikou, T. Interleukin 8 in human hepatocellular carcinoma correlates with cancer cell invasion of vessels but not with tumor angiogenesis. Ann. Surg. Oncol. 2005, 12, 800-807.
45. Wu, T. Cyclooxygenase-2 in hepatocellular carcinoma. Cancer Treat. Rev. 2006, 32, 28-44.
46. Zhao, Q. T.; Yue, S. Q.; Cui, Z.; Wang, Q.; Cui, X.; Zhai, H. H.; Zhang, L. H.; Dou, K. F. Potential involvement of the cyclooxygenase-2 pathway in hepatocellular carcinoma-associated angiogenesis. Life Sci. 2007, 80, 484-492.
47. Cheng, A. S.; Chan, H. L.; To, K. F.; Leung, W. K.; Chan, K. K.; Liew, C. T.; Sung, J. J. Cyclooxygenase-2 pathway correlates with vascular endothelial growth factor expression and tumor angiogenesis in hepatitis B virus-associated hepatocellular carcinoma. Int. J. Oncol. 2004, 24, 853-860.
48. Tang, T. C.; Poon, R. T.; Lau, C. P.; Xie, D.; Fan, S. T. Tumor cyclooxygenase-2 levels correlate with tumor invasiveness in human hepatocellular carcinoma. World J. Gastroenterol. 2005, 11, 1896-1902.
49. Denda, A.; Kitayama, W.; Kishida, H.; Murata, N.; Tamura, K.; Kusuoka, O.; Tsutsumi, M.; Nishikawa, F.; Kita, E.; Nakae, D.; Konishi, Y.; Kuniyasu, H. Expression of inducible nitric oxide (NO) synthase but not prevention by its gene ablation of hepatocarcinogenesis with fibrosis caused by a choline-deficient, L-amino acid-defined diet in rats and mice. Nitric Oxide 2007, 16, 164-176.
50. Calvisi, D. F.; Pinna, F.; Ladu, S.; Pellegrino, R.; Muroni, M. R.; Simile, M. M.; Frau, M.; Tomasi, M. L.; De Miglio, M. R.; Seddaiu, M. A.; Daino, L.; Sanna, V.; Feo, F.; Pascale, R. M. Aberrant iNOS signaling is under genetic control in rodent liver cancer and potentially prognostic for the human disease. Carcinogenesis 2008, 29, 1639-1647.
51. Rahman, M. A.; Dhar, D. K.; Yamaguchi, E.; Maruyama, S.; Sato, T.; Hayashi, H.; Ono, T.; Yamanoi, A.; Kohno, H.; Nagasue, N. Coexpression of inducible nitric oxide synthase and COX 2 in hepatocellular carcinoma and surrounding liver: possible involvement of COX-2 in the angiogenesis of hepatitis C viruspositive cases. Clin. Cancer Res. 2001, 7, 1325-1332.
52. Guo, R. P.; Zhong, C.; Shi, M.; Zhang, C. Q.; Wei, W.; Zhang, Y. Q.; Li, J. Q. Clinical value of apoptosis and angiogenesis factors in estimating the prognosis of hepatocellular carcinoma. J. Cancer Res. Clin. Oncol. 2006, 132, 547-555.
53. Kim, S.; Park, H. S.; Son, H. J.; Moon, W. S. The role of angiostatin, vascular endothelial growth factor, matrix metalloproteinase 9 and 12 in the angiogenesis of hepatocellular carcinoma. Korean J. Hepatol. 2004, 10, 62-72.
54. Sun, M. H.; Han, X. C.; Jia, M. K.; Jiang, W. D.; Wang, M.; Zhang, H.; Han, G,; Jiang, Y. Expressions of inducible nitric oxide synthase and matrix metalloproteinase-9 and their effects on angiogenesis and progression of hepatocellular carcinoma. World J. Gastroenterol. 2005, 11, 5931-5937.
55. Tai, D. I.; Tsai, S. L.; Chang, Y. H.; Huang, S. N.; Chen, T. C.; Chang, K. S.; Liaw, Y. F. Constitutive activation of nuclear factor kappaB in hepatocellular carcinoma. Cancer 2000, 89, 2274-2281.
56. Qiao, L.; Zhang, H.; Yu, J.; Francisco, R.; Dent, P.; Ebert, M. P.; Röcken, C.; Farrell, G. Constitutive activation of NF-kappaB in human hepatocellular carcinoma: evidence of a cytoprotective role. Hum. Gene Ther. 2006, 17, 280-290.
57. Sethi, G.; Sung, B.; Aggarwal, B. B. Nuclear factor-κB: from bench to bedside. Exp. Biol. Med. 2008, 233, 21-31.
58. Ralhan, R.; Pandey, M. K.; Aggarwal, B. B. Nuclear factor-kappa B links carcicinogenesis and chemopreventive agents. Front. Biosci. (Schol. Ed.) 2009, 1, 45-60.
59. Futakuchi, M.; Ogawa, K.; Tamano, S.; Takahashi, S.; Shirai, T. Suppression of metastasis by nuclear factor kappaB inhibitors in an in vivo lung metastasis model of chemically induced hepatocellular carcinoma. Cancer Sci. 2004, 95, 18-24.
60. Liu, L. P.; Liang, H. F.; Chen, X. P.; Zhang, W. G.; Yang, S. L.; Xu, T.; Ren, L. The role of NF-kappaB in Hepatitis b virus X protein-mediated upregulation of VEGF and MMPs. Cancer Invest. 2010, 28, 443-451.
61. Morinaga, S.; Yamamoto, Y.; Noguchi, Y.; Imada, T.; Rino, Y.; Akaike, M.; Sugimasa, Y.; Takemiya, S.; Takanashi, Y. Plateletderived endothelial cell growth factor (PD-ECGF) is up-regulated in human hepatocellular carcinoma (HCC) and the corresponding hepatitis liver. Hepatogastroenterology 2003, 50, 1521-1526.
62. Ezaki, T.; Ikegami, T.; Maeda, T.; Yamada, T.; Ishida, T.; Hashizume, M.; Maehara, Y. Prognostic value of thymidine phosphorylase activity in liver tissue adjacent to hepatocellular carcinoma. Int. J. Clin. Oncol. 2005, 10, 171-176.
63. Asahara, T.; Murohara, T.; Sullivan, A.; Silver, M.; van der Zee, R.; Li, T.; Witzenbichler, B.; Schatteman, G.; Isner, J. M. Isolation of putative progenitor endothelial cells for angiogenesis. Science 1997, 275, 964-967.
64. El-Assal, O. N.; Yamanoi, A.; Ono, T.; Kohno, H.; Nagasue, N. The clinicopathological significance of heparanase and basic fibroblast growth factor expressions in hepatocellular carcinoma. Clin. Cancer Res. 2001, 7, 1299-1305.
65. Motoo, Y.; Sawabu, N.; Yamaguchi, Y.; Terada, T.; Nakanuma, Y. Sinusoidal capillarization of human hepatocellular carcinoma: possible promotion by fibroblast growth factor. Oncology 1993, 50, 270-274.
66. Horiguchi, N.; Takayama, H.; Toyoda, M.; Otsuka, T.; Fukusato, T.; Merlino, G.; Takagi, H; Mori, M. Hepatocyte growth factor promotes hepatocarcinogenesis through c-Met autocrine activation and enhanced angiogenesis in transgenic mice treated with diethylnitrosamine. Oncogene 2002, 21, 1791-1799.
67. Xu, Z.; Shen, M. X.; Ma, D. Z.; Wang, L. Y.; Zha, X. L. TGFbeta1-promoted epithelial-to-mesenchymal transformation and cell adhesion contribute to TGF-beta1-enhanced cell migration in SMMC-7721 cells. Cell Res. 2003, 13, 343-350.
68. Ito, N.; Kawata, S.; Tamura, S.; Shirai, Y.; Kiso, S.; Tsushima, H.; Matsuzawa, Y. Positive correlation of plasma transforming growth factor-beta 1 levels with tumor vascularity in hepatocellular carcinoma. Cancer Lett. 1995, 89, 45-48.
69. Benetti, A.; Berenzi, A.; Gambarotti, M.; Garrafa, E.; Gelati, M.; Dessy, E.; Portolani, N.; Piardi, T.; Giulini, S. M.; Caruso, A.; Invernici, G.; Parati, E.A.; Nicosia, R.; Alessandri, G. Transforming growth factor-beta1 and CD105 promote the migration of hepatocellular carcinoma-derived endothelium. Cancer Res. 2008, 68, 8626-8634.
70. Dupuy, E.; Hainaud, P.; Villemain, A.; Bodevin-Phèdre, E.; Brouland, J. P.; Briand, P.; Tobelem, G. Tumoral angiogenesis and tissue factor expression during hepatocellular carcinoma progression in a transgenic mouse model. J. Hepatol. 2003, 38, 793-802.
71. Poon, R. T.; Lau, C. P.; Ho, J. W.; Yu, W. C.; Fan, S. T.; Wong, J. Tissue factor expression correlates with tumor angiogenesis and invasiveness in human hepatocellular carcinoma. Clin. Cancer Res. 2003, 9, 5339-5345.
72. Torimura, T.; Ueno, T.; Kin, M.; Harada, R.; Taniguchi, E.; Nakamura, T.; Sakata, R.; Hashimoto, O.; Sakamoto, M.; Kumashiro, R.; Sata, M.; Nakashima, O.; Yano, H.; Kojiro, M. Overexpression of angiopoietin-1 and angiopoietin-2 in hepatocellular carcinoma. J. Hepatol. 2004, 40, 799-807.
73. Mitsuhashi, N.; Shimizu, H.; Ohtsuka, M.; Wakabayashi, Y.; Ito, H.; Kimura F.; Yoshidome, H.; Kato, A.; Nukui, Y.; Miyazaki, M. Angiopoietins and Tie-2 expression in angiogenesis and proliferation of human hepatocellular carcinoma. Hepatology 2003, 37, 1105-1113.
74. Wada, H.; Nagano, H.; Yamamoto, H.; Yang, Y.; Kondo, M.; Ota, H.; Nakamura, M.; Yoshioka, S.; Kato, H.; Damdinsuren, B.; Tang, D.; Marubashi, S.; Miyamoto, A.; Takeda, Y.; Umeshita, K.; Nakamori, S.; Sakon, M.; Dono, K.; Wakasa, K.; Monden, M. Expression pattern of angiogenic factors and prognosis after hepatic resection in hepatocellular carcinoma: importance of angiopoietin-2 and hypoxia-induced factor-1 alpha. Liver Int. 2006, 26, 414-423.
75. Weiner, H. L.; Weiner, L. H.; Swain, J. L. Tissue distribution and developmental expression of the messenger RNA encoding angiogenin. Science 1987, 237, 280-282.
76. Burgmann, H.; Hollenstein, U.; Maca, T.; Zedwitz-Liebenstein, K.; Thalhammer, F.; Koppensteiner, R.; Ehringer, H.; Graninger, W. Increased serum laminin and angiogenin concentrations in patients with peripheral arterial occlusive disease. J. Clin. Pathol. 1996, 49, 508-510.
77. Hisai, H.; Kato, J.; Kobune, M.; Murakami, T.; Miyanishi, K.; Takahashi, M.; Yoshizaki, N.; Takimoto, R.; Terui, T.; Niitsu, Y. Increased expression of angiogenin in hepatocellular carcinoma in correlation with tumor vascularity. Clin. Cancer Res. 2003, 9, 4852-4859.
78. Lawler, J. Thrombospondin-1 as an endogenous inhibitor of angiogenesis and tumor growth. J. Cell Mol. Med. 2002, 6, 1-12.
79. Kawahara, N.; Ono, M.; Taguchi, K.; Okamoto, M.; Shimada, M.; Takenaka, K.; Hayashi, K.; Mosher, D. F.; Sugimachi, K.; Tsuneyoshi, M.; Kuwano, M. Enhanced expression of thrombospondin-1 and hypovascularity in human cholangiocarcinoma. Hepatology 1998, 28, 1512-1517.
80. Poon, R. T.; Chung, K. K.; Cheung, S. T.; Lau, C. P.; Tong, S. W.; Leung, K. L.; Yu, W. C.; Tuszynski, G. P.; Fan, S. T. Clinical significance of thrombospondin 1 expression in hepatocellular carcinoma. Clin. Cancer Res. 2004, 10, 4150-4157.
81. Gorrin-Rivas, M. J.; Arii, S.; Mori, A.; Takeda, Y.; Mizumoto, M.; Furutani, M.; Imamura, M. Implications of human macrophage metalloelastase and vascular endothelial growth factor gene expression in angiogenesis of hepatocellular carcinoma. Ann. Surg. 2000, 231, 67-73.
82. Kim, J. S.; Yu, H. K.; Ahn, J. H.; Lee, H. J.; Hong, S. W.; Jung, K. H.; Chang, S. I.; Hong, Y. K.; Joe, Y. A.; Byun, S. M.; Lee, S. K.; Chung, S. I.; Yoon, Y. Human apolipoprotein(a) kringle V inhibits angiogenesis in vitro and in vivo by interfering with the activation of focal adhesion kinases. Biochem. Biophys. Res. Commun. 2004, 313, 534-540.
83. Musso, O.; Rehn, M.; Théret, N.; Turlin, B.; Bioulac-Sage, P.; Lotrian, D.; Campion, J. P.; Pihlajaniemi, T.; Clément, B. Tumor progression is associated with a significant decrease in the expression of the endostatin precursor collagen XVIII in human hepatocellular carcinomas. Cancer Res. 2001, 61, 45-49.
84. Dhar, D. K.; Ono, T.; Yamanoi, A.; Soda, Y.; Yamaguchi, E.; Rahman, M. A.; Kohno, H.; Nagasue, N. Serum endostatin predicts tumor vascularity in hepatocellular carcinoma. Cancer 2002, 95, 2188-2195.
85. Yoshiji, H.; Kuriyama, S.; Kawata. M.; Yoshii, J.; Ikenaka, Y.; Noguchi, R.; Nakatani, T.; Tsujinoue, H.; Fukui, H. The angiotensin-I-converting enzyme inhibitor perindopril suppresses tumor growth and angiogenesis: possible role of the vascular endothelial growth factor. Clin. Cancer Res. 2001, 7, 1073-1078.
86. Yoshiji, H.; Yoshii, J.; Ikenaka, Y.; Noguchi, R.; Yanase, K.; Tsujinoue, H.; Imazu, H.; Fukui, H. Suppression of the reninangiotensin system attenuates vascular endothelial growth factormediated tumor development and angiogenesis in murine hepatocellular carcinoma cells. Int. J. Oncol. 2002, 20, 1227-1231.
87. Pestka, S.; Langer, J. A.; Zoon, K.C.; Samuel, C. E. Interferons and their actions. Annu. Rev. Biochem. 1987, 56, 727-777.
88. Noguchi, R.; Yoshiji, H.; Kuriyama, S.; Yoshii, J.; Ikenaka, Y.; Yanase, K.; Namisaki, T.; Kitade, M.; Yamazaki, M.; Mitoro, A.; Tsujinoue, H.; Imazu, H.; Masaki, T.; Fukui, H. Combination of interferon-beta and the angiotensin-converting enzyme inhibitor, perindopril, attenuates murine hepatocellular carcinoma development and angiogenesis. Clin. Cancer Res. 2003, 9, 6038-6045.
89. Yoshiji, H.; Noguchi, R.; Kuriyama, S.; Yoshii, J.; Ikenaka, Y. Combination of interferon and angiotensin-converting enzyme inhibitor, perindopril, suppresses liver carcinogenesis and angiogenesis in mice. Oncol. Rep. 2005, 13, 491-495.
90. Jancin, B. Vitamin K cuts hepatocellular carcinoma mortality. Fam. Pract. News 2002, 32.
91. 2 and the angiotensinconverting enzyme inhibitor, perindopril, attenuates the liver enzyme-altered preneoplastic lesions in rats via angiogenesis suppression. J. Hepatol. 2005, 42, 687-693.
92. 2 and angiotensin-converting enzyme inhibitor via antiangiogenic activities. Oncol. Rep. 2006, 15, 155-159.
93. Yanase, K.; Yoshiji, H.; Ikenaka, Y.; Noguchi, R.; Kitade, M.; Kaji, K.; Yoshii, J.; Namisaki, T.; Yamazaki, M.; Asada, K.; Tsujimoto, T.; Akahane, T.; Uemura, M.; Fukui, H. Synergistic inhibition of hepatocellular carcinoma growth and hepatocarcinogenesis by combination of 5-fluorouracil and angiotensin-converting enzyme inhibitor via anti-angiogenic activities. Oncol. Rep. 2007, 17, 441-446.
94. Ishikawa, H.; Nakao, K.; Matsumoto, K.; Ichikawa, T.; Hamasaki, K.; Nakata, K.; Eguchi, K. Antiangiogenic gene therapy for hepatocellular carcinoma using angiostatin gene. Hepatology 2003, 37, 696-704.
95. Liu, H.; Peng, C. H.; Liu, Y. B.; Wu, Y. L.; Zhao, Z. M.; Wang, Y.; Han, B. S. Inhibitory effect of adeno-associated virus-mediated gene transfer of human endostatin on hepatocellular carcinoma. World J. Gastroenterol. 2005, 11, 3331-3334.
96. Ingber, D.; Fujita, T.; Kishimoto, S.; Sudo, K.; Kanamaru, T.; Brem, H.; Folkman, J. Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumour growth. Nature 1990, 348, 555-557.
97. Tanaka, H.; Taniguchi, H.; Mugitani, T.; Koishi, Y.; Masuyama, M.; Higashida, T.; Koyama, H.; Suganuma, Y.; Miyata, K.; Takeuchi, K.; Takahashi, T. Intra-arterial administration of the angiogenesis inhibitor TNP-470 blocks liver metastasis in a rabbit model. Br. J. Cancer 1995, 72, 650-653.
98. Kin, M.; Torimura, T.; Ueno, T.; Nakamura, T.; Ogata, R.; Sakamoto, M.; Tamaki, S.; Sata, M. Angiogenesis inhibitor TNP-470 suppresses the progression of experimentally-induced hepatocellular carcinoma in rats. Int. J. Oncol. 2000, 16, 375-382.
99. Mauriz, J. L.; Gonzalez, P.; Duran, M. C.; Molpeceres, V.; Culebras, J. M.; Gonzalez-Gallego, J. Cell-cycle inhibition by TNP-470 in an in vivo model of hepatocarcinoma is mediated by a p53 and p21WAF1/CIP1 mechanism. Transl. Res. 2007, 149, 46-53.
100. Terano, H.; Shibata, T.; Otsuka, T. Angiogenesis inhibitors of microbial origin. Drug Future 1993, 18, 239.
101. Ishii, Y.; Sakamoto, T.; Ito, R.; Yanaga, K. Anti-angiogenic therapy on hepatocellular carcinoma development and progression. J. Surg. Res. 2010, 158, 69-76.
102. Puerta-Fernández, E.; Romero-López, C.; Barroso-delJesus, A.; Berzal-Herranz, A. Ribozymes: recent advances in the development of RNA tools. FEMS Microbiol. Rev. 2003, 27, 75-97.
103. Li, L. H.; Guo, Z. J.; Yan, L. L.; Yang, J. C.; Xie, Y. F.; Sheng, W. H.; Huang, Z. H.; Wang XH. Antitumor and antiangiogenic activities of anti-vascular endothelial growth factor hairpin ribozyme in human hepatocellular carcinoma cell cultures and xenografts. World J. Gastroenterol. 2007, 13, 6425-6432.
104. Wang, L.; Park, H.; Chhim, S.; Ding, Y.; Jiang, W.; Queen, C.; Kim, K. J. A novel monoclonal antibody to fibroblast growth factor 2 effectively inhibits growth of hepatocellular carcinoma xenografts. Mol. Cancer Ther. 2012, 11, 864-872.
105. Zhang, D.; Li, B.; Shi, J.; Zhao, L.; Zhang, X.; Wang, C.; Hou, S.; Qian, W.; Kou, G.; Wang, H.; Guo, Y. Suppression of tumor growth and metastasis by simultaneously blocking vascular endothelial growth factor (VEGF)-A and VEGF-C with a receptorimmunoglobulin fusion protein. Cancer Res. 2010, 70, 2495-2503.
106. Wang, L.; Wu, W. Z.; Sun, H. C.; Wu, X. F.; Qin, L. X.; Liu, Y. K.; Liu, K. D.; Tang, Z. Y. Mechanism of interferon alpha on inhibition of metastasis and angiogenesis of hepatocellular carcinoma after curative resection in nude mice. J. Gastrointest. Surg. 2003, 7, 587-594.
107. Ogasawara, S.; Yano, H.; Momosaki, S.; Akiba, J.; Nishida, N.; Kojiro, S.; Moriya, F.; Ishizaki, H.; Kuratomi, K.; Kojiro, M. Growth inhibitory effects of IFN-β on human liver cancer cells in vitro and in vivo. J. Interferon Cytokine Res. 2007, 27, 507-516.
108. Harada, N.; Shimada, M.; Okano, S.; Suehiro, T.; Soejima, Y.; Tomita, Y.; Maehara, Y. IL-12 gene therapy is an effective therapeutic strategy for hepatocellular carcinoma in immunosuppressed mice. J. Immunol. 2004, 173, 6635-6644.
109. Lo, C. H.; Chang, C. M.; Tang, S. W.; Pan, W. Y.; Fang, C. C.; Chen, Y.; Wu, P. Y.; Chen, K. Y.; Ma, H. I.; Xiao, X.; Tao, M. H. Differential antitumor effect of interleukin-12 family cytokines on orthotopic hepatocellular carcinoma. J. Gene Med. 2010, 12, 423-434.
110. Xie, Y.; Sheng, W.; Xiang, J.; Ye, Z.; Yang, J. Interleukin-17F suppresses hepatocarcinoma cell growth via inhibition of tumor angiogenesis. Cancer Invest. 2010, 28, 598-607.
111. Chada, S.; Sutton, R. B.; Ekmekcioglu, S.; Ellerhorst, J.; Mumm, J. B.; Leitner, W. W.; Yang, H. Y.; Sahin, A. A.; Hunt, K. K.; Fuson, K. L.; Poìndexter, N.; Roth, J. A.; Ramesh, R.; Grimm, E. A.; Mhashilkar, A. M. MDA-7/IL-24 is a unique cytokine-tumor suppressor in the IL-10 family. Int. Immunopharmacol. 2004, 4, 649-667.
112. Wang, X.; Ye, Z.; Zhong, J.; Xiang, J.; Yang J. Adenovirusmediated Il-24 expression suppresses hepatocellular carcinoma growth via induction of cell apoptosis and cycling arrest and reduction of angiogenesis. Cancer Biother. Radiopharm. 2007, 22, 56-63.
113. Fujita, T.; Inoue, K.; Yamamoto, S.; Ikumoto, T.; Sasaki, S.; Toyama, R.; Chiba, K.; Hoshino, Y.; Okumoto, T. Fungal metabolites. Part 11. A potent immunosuppressive activity found in Isaria sinclairii metabolite. J. Antibiot. (Tokyo) 1994, 47, 208-215.
114. Sanchez, T.; Estrada-Hernandez, T.; Paik, J. H.; Wu, M. T.; Venkataraman, K.; Brinkmann, V.; Claffey, K.; Hla, T. Phosphorylation and action of the immunomodulator FTY720 inhibits vascular endothelial cell growth factor-induced vascular permeability. J. Biol. Chem. 2003, 278, 47281-47290.
115. Ho, J. W.; Man, K.; Sun, C. K.; Lee, T. K.; Poon, R. T.; Fan, S. T. Effects of a novel immunomodulating agent, FTY720, on tumor growth and angiogenesis in hepatocellular carcinoma. Mol. Cancer Ther. 2005, 4, 1430-1438.
116. Wang, Z.; Zhou, J.; Fan, J.; Tan, C. J.; Qiu, S. J.; Yu, Y.; Huang, X. W.; Tang, Z. Y. Sirolimus inhibits the growth and metastatic progression of hepatocellular carcinoma. J. Cancer Res. Clin. Oncol. 2009, 135, 715-722.
117. Quiles-Perez, R.; Muñoz-Gámez, J. A.; Ruiz-Extremera, A.; O'Valle, F.; Sanjuán-Nuñez, L.; Martín-Alvarez, A. B.; Martín-Oliva, D.; Caballero, T.; Muñoz de Rueda, P.; León, J.; Gonzalez, R.; Muntané, J.; Oliver, F.J.; Salmerón, J. Inhibition of poly adenosine diphosphate-ribose polymerase decreases hepatocellular carcinoma growth by modulation of tumor-related gene expression. Hepatology 2010, 51, 255-266.
118. Jia, W. D.; Xu, G. L.; Sun, H. C.; Wang, L.; Xu, R. N.; Xue, Q. Effect of octreotide on angiogenesis induced by hepatocellular carcinoma in vivo. Hepatobiliary Pancreat. Dis. Int. 2003, 2, 404-409.
119. Jia, W. D.; Xu, G. L.; Xu, R. N.; Sun, H. C.; Wang, L.; Yu, J. H.; Wang, J.; Li, J. S.; Zhai, Z. M.; Xue, Q. Octreotide acts as an antitumor angiogenesis compound and suppresses tumor growth in nude mice bearing human hepatocellular carcinoma xenografts. J. Cancer Res. Clin. Oncol. 2003, 129, 327-334.
120. Borbath, I.; Leclercq, I.A.; Sempoux, C.; Abarca-Quinones, J.; Desaeger, C.; Horsmans, Y. Efficacy of lanreotide in preventing the occurrence of chemically induced hepatocellular carcinoma in rats. Chem.-Biol. Interact. 2010, 183, 238-248.
121. Huynh, H.; Chow, P. K.; Tai, W. M.; Choo, S. P.; Chung, A. Y.; Ong, H. S.; Soo, K. C.; Ong, R.; Linnartz, R.; Shi, M. M. Dovitinib demonstrates antitumor and antimetastatic activities in xenograft models of hepatocellular carcinoma. J. Hepatol. 2012, 56, 595-601.
122. Huynh, H.; Ong, R.; Soo, K. C. Foretinib demonstrates anti-tumor activity and improves overall survival in preclinical models of hepatocellular carcinoma. Angiogenesis 2012, 15, 59-70.
123. Liu, Y.; Poon, R. T.; Li, Q.; Kok, T. W.; Lau, C.; Fan, S. T. Both antiangiogenesis-and angiogenesis-independent effects are responsible for hepatocellular carcinoma growth arrest by tyrosine kinase inhibitor PTK787/ZK222584. Cancer Res. 2005, 65, 3691-3699.
124. Wilhelm, S. M.; Carter, C.; Tang, L.; Wilkie, D.; McNabola, A.; Rong, H.; Chen, C.; Zhang, X.; Vincent, P.; McHugh, M.; Cao, Y.; Shujath, J.; Gawlak, S.; Eveleigh, D.; Rowley, B.; Liu, L.; Adnane, L.; Lynch, M.; Auclair, D.; Taylor, I.; Gedrich, R.; Voznesensky, A.; Riedl, B.; Post, L. E.; Bollag, G.; Trail, P. A. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res. 2004, 64, 7099-7109.
125. Liu, L.; Cao, Y.; Chen, C.; Zhang, X.; McNabola, A.; Wilkie, D.; Wilhelm, S.; Lynch, M.; Carter, C. Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. Cancer Res. 2006, 66, 11851-11858.
126. Wang, Z.; Zhou, J.; Fan, J.; Qiu, S. J.; Yu, Y.; Huang, X. W.; Tang, Z. Y. Effect of rapamycin alone and in combination with sorafenib in an orthotopic model of human hepatocellular carcinoma. Clin. Cancer Res. 2008, 14, 5124-5130.
127. Faivre, S.; Demetri, G.; Sargent, W.; Raymond, E. Molecular basis for sunitinib efficacy and future clinical development. Nat. Rev. Drug Discov. 2007, 6, 734-745.
128. Huynh, H.; Ngo, V. C.; Choo, S. P.; Poon, D.; Koong, H. N.; Thng, C. H.; Toh, H. C.; Zheng, L.; Ong, L. C.; Jin, Y.; Song, I. C.; Chang, A. P.; Ong, H. S.; Chung, A. Y.; Chow, P. K.; Soo, K. C. Sunitinib (SUTENT, SU11248) suppresses tumor growth and induces apoptosis in xenograft models of human hepatocellular carcinoma. Curr. Cancer Drug Targets 2009, 9, 738-747.
129. Yoshiji, H.; Kuriyama, S.; Yoshii, J.; Ikenaka, Y.; Noguchi, R.; Hicklin, D. J.; Wu, Y.; Yanase, K.; Namisaki, T.; Kitade, M.; Yamazaki, M.; Tsujinoue, H.; Masaki, T.; Fukui H. Halting the interaction between vascular endothelial growth factor and its receptors attenuates liver carcinogenesis in mice. Hepatology 2004, 39, 1517-1524.
130. Lee, H. C.; Kim, M.; Wands, J.R. Wnt/Frizzled signaling in hepatocellular carcinoma. Front. Biosci. 2006, 11, 1901-1915.
131. Nejak-Bowen, K. N.; Monga, S. P. Beta-catenin signaling, liver regeneration and hepatocellular cancer: sorting the good from the bad. Semin. Cancer Biol. 2011, 21, 44-58.
132. Hu, J.; Dong, A.; Fernandez-Ruiz, V.; Shan, J.; Kawa, M.; Martínez-Ansó, E.; Prieto, J.; Qian, C. Blockade of Wnt signaling inhibits angiogenesis and tumor growth in hepatocellular carcinoma. Cancer Res. 2009, 69, 6951-6959.
133. Man, K.; Ng, K. T.; Xu, A.; Cheng, Q.; Lo, C. M.; Xiao, J. W.; Sun, B. S.; Lim, Z. X.; Cheung, J. S.; Wu, E. X.; Sun, C. K.; Poon, R. T.; Fan, S. T. Suppression of liver tumor growth and metastasis by adiponectin in nude mice through inhibition of tumor angiogenesis and downregulation of Rho kinase/IFN-inducible protein 10/matrix metalloproteinase 9 signaling. Clin. Cancer Res. 2010, 16, 967-977.
134. Liu, B.; Pan, S.; Dong, X.; Qiao, H.; Jiang, H.; Krissansen, G. W.; Sun X. Opposing effects of arsenic trioxide on hepatocellular carcinomas in mice. Cancer Sci. 2006, 97, 675-681.
135. Yu, S. J.; Yoon, J. H.; Yang, J. I., Cho, E. J.; Kwak, M. S.; Jang, E. S.; Lee, J. H.; Kim, Y. J.; Lee, H. S.; Kim, C. Y. Enhancement of hexokinase II inhibitor-induced apoptosis in hepatocellular carcinoma cells via augmenting ER stress and anti-angiogenesis by protein disulfide isomerase inhibition. J. Bioenerg. Biomembr. 2012, 44, 101-115.
136. Davies, B.; Brown, P. D.; East, N.; Crimmin, M. J.; Balkwill, F. R. A synthetic matrix metalloproteinase inhibitor decreases tumor burden and prolongs survival of mice bearing human ovarian carcinoma xenografts. Cancer Res. 1993, 53, 2087-2091.
137. Bu, W.; Tang, Z. Y.; Sun, F. X.; Ye, S. L.; Liu, K. D.; Xue, Q.; Chen, J.; Gao, D. M. Effects of matrix metalloproteinase inhibitor BB-94 on liver cancer growth and metastasis in a patient-like orthotopic model LCI-D20. Hepatogastroenterology 1998, 45, 1056-1061.
138. Marchesini, G.; Bianchi, G.; Merli, M.; Amodio, P.; Panella, C.; Loguercio, C.; Rossi Fanelli, F.; Abbiati, R.; Italian BCAA Study Group. Nutritional supplementation with branched-chain amino acids in advanced cirrhosis: a double-blind, randomized trial. Gastroenterology 2003, 124, 1792-1801.
139. Muto, Y.; Sato, S.; Watanabe, A.; Moriwaki, H.; Suzuki, K.; Kato, A.; Kato, M.; Nakamura, T.; Higuchi, K.; Nishiguchi, S.; Kumada, H.; Long-Term Survival Study Group. Effects of oral branched-chain amino acid granules on event-free survival in patients with liver cirrhosis. Clin. Gastroenterol. Hepatol. 2005, 3, 705-713.
140. Yoshiji, H,; Noguchi, R.; Kitade, M.; Kaji, K.; Ikenaka, Y.; Namisaki, T.; Yoshii, J.; Yanase, K.; Yamazaki, M.; Tsujimoto, T.; Akahane, T.; Kawaratani, H.; Uemura, M.; Fukui. H. Branchedchain amino acids suppress insulin-resistance-based hepatocarcinogenesis in obese diabetic rats. J. Gastroenterol. 2009, 44, 483-491.
141. Yoshiji, H.; Noguchi, R.; Kaji, K.; Ikenaka, Y.; Shirai, Y.; Namisaki, T.; Kitade, M.; Tsujimoto, T.; Kawaratani, H.; Fukui, H. Attenuation of insulin-resistance-based hepatocarcinogenesis and angiogenesis by combined treatment with branched-chain amino acids and angiotensin-converting enzyme inhibitor in obese diabetic rats. J. Gastroenterol. 2010, 45, 443-450.
142. Pines, M.; Knopov, V.; Genina, O.; Lavelin, I.; Nagler, A. Halofuginone, a specific inhibitor of collagen type I synthesis, prevents dimethylnitrosamine-induced liver cirrhosis. J. Hepatol. 1997, 27, 391-398.
143. Bruck, R.; Genina, O.; Aeed, H.; Alexiev, R.; Nagler, A.; Avni, Y.; Pines, M. Halofuginone to prevent and treat thioacetamide-induced liver fibrosis in rats. Hepatology 2001, 33, 379-386.
144. Taras, D.; Blanc, J. F.; Rullier, A.; Dugot-Senant, N.; Laurendeau, I.; Bièche, I.; Pines, M.; Rosenbaum J. Halofuginone suppresses the lung metastasis of chemically induced hepatocellular carcinoma in rats through MMP inhibition. Neoplasia 2006, 8, 312-318.
145. McLean, J. W.; Tomlinson, J. E.; Kuang, W. J.; Eaton, D. L.; Chen, E. Y.; Fless, G. M.; Scanu, A. M.; Lawn, R. M. cDNA sequence of human apolipoprotein(a) is homologous to plasminogen. Nature 1987, 330, 132-137.
146. Kim, J. S.; Chang, J. H.; Yu, H. K.; Ahn, J. H.; Yum, J. S.; Lee, S. K.; Jung, K. H.; Park, D. H.; Yoon, Y.; Byun, S. M.; Chung S. I. Inhibition of angiogenesis and angiogenesis-dependent tumor growth by the cryptic kringle fragments of human apolipoprotein(a). J. Biol. Chem. 2003, 278, 29000-29008.
147. Yu, H. K.; Kim, J. S.; Lee, H. J.; Ahn, J. H.; Lee, S. K.; Hong, S. W.; Yoon, Y. Suppression of colorectal cancer liver metastasis and extension of survival by expression of apolipoprotein(a) kringles. Cancer Res. 2004, 64, 7092-7098.
148. Lee, K.; Yun, S. T.; Kim, Y. G.; Yoon, Y.; Jo, E. C. Adenoassociated virus-mediated expression of apolipoprotein (a) kringles suppresses hepatocellular carcinoma growth in mice. Hepatology 2006, 43, 1063-1073.
149. Qin, L. X.; Tang, Z. Y.; Li, X. M.; Bu, W.; Xia, J. L. Effect of antiangiogenic agents on experimental animal models of hepatocarcinoma. Ann. Acad. Med. Singapore 1999, 28, 147-151.
150. D'Amato, R. J.; Loughnan, M. S.; Flynn, E.; Folkman, J. Thalidomide is an inhibitor of angiogenesis. Proc. Natl. Acad. Sci. USA 1994, 91, 4082-4085.
151. Zhang, Z. L.; Liu, Z. S.; Sun, Q. Effects of thalidomide on angiogenesis and tumor growth and metastasis of human hepatocellular carcinoma in nude mice. World J. Gastroenterol. 2005, 11, 216-220.
152. Dong, Z. Z.; Yao, D. F.; Wu, W.; Yao, M.; Yu, H. B.; Shen, J. J.; Qiu, L. W.; Yao, N. H.; Sai, W. L.; Yang, J. L. Delayed hepatocarcinogenesis through antiangiogenic intervention in the nuclear factor-kappa B activation pathway in rats. Hepatobiliary Pancreat. Dis. Int. 2010, 9, 169-174.
153. Ziche, M.; Jones, J.; Gullino, P. M. Role of prostaglandin E1 and copper in angiogenesis. J. Natl. Cancer Inst. 1982, 69, 475-482.
154. Honda, H.; Onitsuka, H.; Kanazawa, Y.; Matsumata, T.; Hayashi, T.; Kaneko, K.; Fukuya, T.; Tateshi, Y.; Adachi, E.; Masuda, K. MR imaging of hepatocellular carcinoma. Correlation of metal content and signal intensity. Acta Radiol. 1995, 36, 163-167.
155. Yoshiji, J.; Yoshiji, H.; Kuriyama, S.; Ikenaka, Y.; Noguchi, R.; Okuda, H.; Tsujinoue, H.; Nakatani, T.; Kishida, H.; Nakae, D.; Gomez, D. E.; De Lorenzo, M. S.; Tejera, A. M.; Fukui, H. The copper-chelating agent, trientine, suppresses tumor development and angiogenesis in the murine hepatocellular carcinoma cells. Int. J. Cancer 2001, 94, 768-773.
156. Yoshiji, H.; Kuriyama, S.; Yoshii, J.; Ikenaka, Y.; Noguchi, R.; Yanase, K.; Namisaki, T.; Yamazaki, M.; Tsujinoue, H.; Imazu, H.; Fukui, H. The copper-chelating agent, trientine, attenuates liver enzyme-altered preneoplastic lesions in rats by angiogenesis suppression. Oncol. Rep. 2003, 10, 1369-1373.
157. Moriguchi, M.; Nakajima, T.; Kimura, H.; Watanabe, T.; Takashima, H.; Mitsumoto, Y.; Katagishi, T.; Okanoue, T.; Kagawa, K. The copper chelator trientine has an antiangiogenic effect against hepatocellular carcinoma, possibly through inhibition of interleukin-8 production. Int. J. Cancer 2002, 102, 445-452.
158. Sudhakar, A.; Sugimoto, H.; Yang, C.; Lively, J.; Zeisberg, M.; Kalluri, R. Human tumstatin and human endostatin exhibit distinct antiangiogenic activities mediated by alpha v beta 3 and alpha 5 beta 1 integrins. Proc. Natl. Acad. Sci. USA 2003, 100, 4766-4771.
159. Goto, T.; Ishikawa, H.; Matsumoto, K.; Nishimura, D.; Kusaba, M.; Taura, N.; Shibata, H.; Miyaaki, H.; Ichikawa, T.; Hamasaki, K.; Nakao, K.; Maeshima, Y.; Eguchi, K. Tum-1, a tumstatin fragment, gene delivery into hepatocellular carcinoma suppresses tumor growth through inhibiting angiogenesis. Int. J. Oncol. 2008, 33, 33-40.
160. Janani, P.; Sivakumari, K.; Geetha, A.; Ravisankar, B.; Parthasarathy, C. Chemopreventive effect of bacoside A on N-nitrosodiethylamineinduced hepatocarcinogenesis in rats. J. Cancer Res. Clin. Oncol. 2010, 136, 759-770.
161. Janani, P.; Sivakumari, K.; Geetha, A.; Ravisankar, B.; Parthasarathy, C. Bacoside A downregulates matrix metalloproteinases 2 and 9 in DENA-induced hepatocellular carcinoma. Cell Biochem. Funct. 2010, 28, 164-169.
162. Shahidi, F.; Arachchi, J.K.V.; Jeon, Y. J. Food applications of chitin and chitosan. Trends Food Sci. Tech. 1999, 10, 37-51.
163. Xu, Y.; Wen, Z.; Xu, Z. Chitosan nanoparticles inhibit the growth of human hepatocellular carcinoma xenografts through an antiangiogenic mechanism. Anticancer Res. 2010, 30, 5103-5110.
164. Yoysungnoen, P.; Wirachwong, P.; Bhattarakosol, P.; Niimi, H.; Patumraj, S. Antiangiogenic activity of curcumin in hepatocellular carcinoma cells implanted nude mice. Clin. Hemorheol. Microcirc. 2005, 33, 127-135.
165. Yoysungnoen, P.; Wirachwong, P.; Bhattarakosol, P.; Niimi, H.; Patumraj, S.; Effects of curcumin on tumor angiogenesis and biomarkers, COX-2 and VEGF, in hepatocellular carcinoma cell-implanted nude mice. Clin. Hemorheol. Microcirc. 2006, 34, 109-115.
166. Yoysungnoen, P.; Wirachwong, P.; Changtam, C.; Suksamrarn, A.; Patumraj S. Anti-cancer and anti-angiogenic effects of curcumin and tetrahydrocurcumin on implanted hepatocellular carcinoma in nude mice. World J. Gasterenterol. 2008, 14, 2003-2009.
167. Shirakami, Y.; Shimizu, M.; Adachi, S.; Sakai, H.; Nakagawa, T.; Yasuda, Y.; Tsurumi, H.; Hara, Y.; Moriwaki, H. (-)-Epigallocatechin gallate suppresses the growth of human hepatocellular carcinoma cells by inhibiting activation of the vascular endothelial growth factor-vascular endothelial growth factor receptor axis. Cancer Sci. 2009, 10, 1957-1962.
168. Chandra Mohan, K. V.; Hara, Y.; Abraham, S. K.; Nagini, S. Comparative evaluation of the chemopreventive efficacy of green and black tea polyphenols in the hamster buccal pouch carcinogenesis model. Clin. Biochem. 2005, 38, 879-886.
169. Murugan, R. S.; Vinothini, G.; Hara, Y.; Nagini S. Black tea polyphenols target matrix metalloproteinases, RECK, proangiogenic molecules and histone deacetylase in a rat hepatocarcinogenesis model. Anticancer Res. 2009, 29, 2301-2305.
170. Gu, Y.; Zhu, C.; Iwamoto, H.; Chen, J. S.; Genistein inhibits invasive potential of human hepatocellular carcinoma by altering cell cycle, apoptosis, and angiogenesis. World J. Gasteroenterol. 2005, 11, 6512-5517.
171. Ma, Y.; Wang, J.; Liu, L.; Zhu, H.; Chen, X.; Pan, S.; Sun, X.; Jiang, H. Genistein potentiates the effect of arsenic trioxide against human hepatocellular carcinoma: role of Akt and nuclear factor-κB. Cancer Lett. 2011, 301, 75-84.
172. Sivaramakrishnan, V.; Shilpa, P. N.; Praveen Kumar, V. R.; Niranjali Devaraj, S. Attenuation of N-nitrosodiethylamine-induced hepatocellular carcinogenesis by a novel flavonol-Morin. Chem.-Biol. Interact. 2008, 171, 79-88.
173. Sivaramakrishnan, V.; Devaraj, S. N. Morin regulates the expression of NF-B-p65, COX-2 and matrix metalloproteinases in diethylnitrosamine induced rat hepatocellular carcinoma. Chem.-Biol. Interact. 2009, 180, 353-359.
174. Yuan, Z. P.; Chen, L. J.; Fan, L. Y.; Tang, M. H.; Yang, G. L.; Yang, H. S.; Du, X. B.; Wang, G. Q.; Yao, W. X.; Zhao, Q. M.; Ye, B.; Wang, R; Diao, P.; Zhang, W.; Wu, H. B.; Zhao, X.; Wei, Y. Q. Liposomal quercetin efficiently suppresses growth of solid tumors in murine models. Clin. Cancer Res. 2006, 12, 3193-3199.
175. Bishayee, A.; Dhir, N. Resveratrol-mediated chemoprevention of diethylnitrosamine-initiated hepatocarcinogenesis: inhibition of cell proliferation and induction of apoptosis. Chem. Biol. Interact. 2009, 10, 131-144.
176. Bishayee, A.; Barnes, K. F.; Bhatia, D.; Darvesh, A. S.; Carroll, R.T. Resveratrol suppresses oxidative stress and inflammatory response in diethylnitrosamine-initiated rat hepatocarcinogenesis. Cancer Prev. Res. 2010, 3, 753-763.
177. Bishayee, A.; Waghray, A.; Barnes, K. F.; Mbimba T.; Bhatia D.; Chatterjee, M.; Darvesh, A. S. Suppression of the inflammatory cascade is implicated in resveratrol chemoprevention of experimental hepatocarcinogenesis. Pharm. Res. 2010, 27, 1080-1091.
178. Yu, H. B.; Zhang, H. F.; Zhang, X.; Li, D. Y.; Xue, H.Z.; Pan, C. E.; Zhao, S. H. Resveratrol inhibits VEGF expression of human hepatocellular carcinoma cells through a NF-B-mediated mechanism. Hepato-Gastroenterology 2010, 57, 1241-1246.
179. Darvesh, A. S.; Bishayee, A. Selenium in the prevention and treatment of hepatocellular carcinoma. Anti-Cancer Agents Med. Chem. 2010, 10, 338-345.
180. 1 in rats. J. Nanjing Agricultural Univ. 2005, 28, 85-89.
181. Liu, J. G.; Zhao, H. J.; Liu, Y. J.; Wang, X. L. Effect of seleniumenriched malt on hepatocarcinogenesis, paraneoplastic syndrome and the hormones regulating blood glucose in rats treated by diethylnitrosamine. Life Sci. 2006, 78, 2315-2321.
182. Liu, J. G.; Zhao, H. J.; Liu, Y.J.; Wang, X. L. Effect of seleniumenriched malt on VEGF and several relevant angiogenic cytokines in diethylnitrosamine-induced hepatocarcinoma rats. J. Trace Elem. Med. Biol. 2010, 24, 52-57.
183. Liu, J. G.; Zhao, H. J.; Liu, Y. J.; Liu, Y. W.; Wang, X. L. Effect of two selenium sources on hepatocarcinogenesis and several angiogenic cytokines in diethylnitrosamine-induced hepatocarcinoma rats. J. Trace Elem. Med. Biol. 2012, in press. PMID: 22425635
184. Ramakrishnan, G.; Raghavendran, H. R.; Vinodhkumar, R.; Devaki, T. Suppression of N-nitrosodiethylamine induced hepatocarcinogenesis by silymarin in rats. Chem. Biol. Interact. 2006, 161, 104-114.
185. Ramakrishnan, G.; Elinos-Báez, C. M.; Jagan, S.; Augustine, T. A.; Kamaraj, S.; Anandakumar, P.; Devaki T. Silymarin downregulates COX-2 expression and attenuates hyperlipidemia during NDEAinduced rat hepatocellular carcinoma. Mol. Cell. Biochem. 2008, 313, 53-61.
186. Ramakrishnan, G.; Jagan, S.; Kamaraj, S.; Anandakumar, P.; Devaki, T. Silymarin attenuated mast cell recruitment thereby decreased the expressions of matrix metalloproteinases-2 and 9 in rat liver carcinogenesis. Invest. New Drugs 2009, 27, 233-240.
187. Presta, L. G.; Chen, H.; O'Conner, S. J.; Chisholm, V.; Meng, Y. G.; Krummen, L.; Winkler, M.; Ferrara, N. Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res. 1997, 57, 4593-4599.
188. Hurwitz, H.; Fenrenbacher, L.; Novotny, W.; Cartwright, T.; Hainsworth, J.; Heim, W.; Berlin, J.; Baron, A.; Griffing, S.; Holmgren, E.; Ferrara, N.; Fyfe, G.; Rogers, B.; Ross, R.; Kabbinavar, F. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colon cancer. N. Engl. J. Med. 2004, 350, 2335-2342.
189. Siegel, A. B.; Cohen, E. I.; Ocean, A.; Lehrer, D.; Goldenberg, A.; Knox, J. J.; Chen, H.; Clark-Garvey, S.; Weinberg, A.; Mandeli, J.; Christos, P.; Mazumdar, M.; Popa, E.; Brown, R. S. Jr; Rafii, S.; Schwartz, J. D. Phase II trial evaluating the clinical and biologic effects of bevacizumab in unresectable hepatocellular carcinoma. J. Clin. Oncol. 2008, 26, 2992-2998.
190. Zhu, A. X.; Blaszkowsky, L. S.; Ryan, D. P.; Clark, J. W.; Muzikansky, A.; Horgan, K.; Sheehan, S.; Hale, K. E.; Enzinger, P. C.; Bhargava, P.; Stuart, K. Phase II study of gemcitabine and oxaliplatin in combination with benacizumab in patients with advanced hepatocellular carcinoma. J. Clin. Oncol. 2006, 24, 1898-1903.
191. Zhu, A. X.; Holalkere, N. S.; Muzikansky, A.; Horgan, K.; Sahani, D. V. Early antiangiogenic activity of bevacizumab evaluated by computed tomography perfusion scan in patients with advanced hepatocellular carcinoma. Oncologist 2008, 13, 120-125.
192. Keating, G. M.; Santoro, A. Sorafenib: a review of its use in advanced hepatocellular carcinoma. Drugs 2009, 69, 223-240.
193. Strumberg, D.; Clark, J. W.; Awada, A.; Moore, M. J.; Richly, H.; Hendlisz, A.; Hirte, A. W.; Eder, J. P.; Lenz, H. J.; Schwartz, B. Safety, pharmacokinetics, and preliminary antitumor activity of sorafenib: a review of four phase I trials in patients with advanced refractory solid tumors. Oncologist 2007, 12, 426-437.
194. Abou-Alfa, G. K.; Schwartz, L.; Ricci, S.; Amadori, D.; Santoro, A.; Figer, A.; De Greve, J.; Douillard, J. Y.; Lathia, C.; Schwartz, B.; Taylor, I.; Moscovici, M.; Saltz, L. B. Phase II study of sarafenib in patients with advanced hepatocellular carcinoma. J. Clin. Oncol. 2006, 24, 4293-4300.
195. Llovet, J. M.; Ricci, S.; Mazzaferro, V.; Hilgard, P.; Gane, E.; Blanc, J. F.; de Oliveira, A. C.; Santaro, A.; Raoul, J. L.; Forner, A.; Schwartz, M.; Porta, C.; Zeuzem, S.; Bolondi, L.; Greten, T. F.; Galle, P. R.; Seitz, J. F.; Borbath, I.; Haussinger, D.; Giannaris, T.; Shan, M.; Moscovici, M.; Voliotis, D.; Bruix, J; SHARP Investigators Study Group. Sorafenib in advanced hepatocellular carcinoma. N. Engl. J. Med. 2008, 359, 378-379.
196. Cheng, A. L.; Kang, Y. K.; Chen, Z.; Tsao, C. J.; Qin, S.; Kim, J.S.; Luo, R.; Feng, J.; Ye, S.; Yang, T.S.; Xu, J.; Sun, Y.; Liang, H.; Liu, J.; Wang, J.; Tak, W. Y.; Pan, H.; Burock, K.; Zou, J.; Voliotis, D.; Guan, Z. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomized, double-blind, placebo-controlled trial. Lancet Oncol. 2009, 10, 25-34.
197. Faivre, S. J.; Bouattour, M.; Dreyer, C.; Raymond, E. Sunitinib in hepatocellular carcinoma: redefining appropriate dosing, schedule, and activity end points. J. Clin. Oncol. 2009, 27, 248-252.
198. Zhu, A. X.; Sahani, D. V.; Duda, D. G.; di Tomaso, E.; Ancukiewicz, M.; Catalano, O. A.; Sindhwani, V.; Blaszkowsky, L. S.; Yoon, S. S.; Lahdenranta, J.; Bhargava, P.; Meyerhardt, J.; Clark, J. W.; Kwak, E. L.; Hezel, A. F.; Miksad, R.; Abrams, T. A.; Enzinger, P. C.; Fuchs, C. S.; Ryan, D. P.; Jain, R. K. Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: a phase II study. J. Clin. Oncol. 2009, 27, 3027-3035.
199. Zhu, A. X.; Duda, D. G.; Sahani, D. V.; Jain, R. K. Development of sunitinib in hepatocellular carcinoma: rationale, early clinical experience, and correlative studies. Cancer J. 2009, 5, 263-268.
200. Faivre, S.; Raymond, E.; Boucher, E.; Douillard, J.; Lim, H. Y.; Kim, J. S.; Zappa, M.; Lanzalone, S.; Lin, X.; Deprimo, S.; Harmon, C.; Ruiz-Garcia, A.; Lechuga, M. J.; Cheng, A. L. Safety and efficacy of sunitinib in patients with advanced hepatocellular carcinoma: an open-label, multicenter, phase II study. Lancet Oncol. 2009, 10, 794-800.
201. Drevs, J.; Muller-Driver, R.; Wittig, C.; Fuxius, S.; Esser, N.; Hugenschmidt, H.; Konerding, M. A.; Allergrini, P. R.; Wood, J.; Hennig, J.; Unger, C.; Marme, D. PTK787/ZK222584, a specific vascular endothelial growth factor-receptor tyrosine kinase inhibitor, affects the anatomy of the tumor vascular bed and the functional vascular properties as detected by dynamic enhanced magnetic resonance imaging. Cancer Res. 2002, 62, 4015-4022.
202. Liu, Y.; Poon, R. T.; Li, Q.; Kok, T. W.; Lau, C.; Fan, S. T. Both antiangiogenesis-and angiogenesis-independent effects are responsible for hepatocellular carcinoma growth arrest by tyrosine kinase inhibitor PTK787/ZK222584. Cancer Res. 2005, 65, 3691-3699.
203. Mross, K.; Drevs, J.; Muller, M.; Medinger, M.; Marme, D.; Henng, J.; Morgan, B.; Lebwohl, D.; Masson, E.; Ho, Y.Y.; Gunther, C.; Laurent, D.; Unger, C. Phase I clinical and pharmacokinetic study of PTK/ZK, a multiple VEGF receptor inhibitor, in patients with liver metastases from solid tumors. Eur. J. Cancer 2005, 41, 1291-1299.
204. Koch, I.; Baron, A.; Roberts, S.; Junker, U.; Palacay-Ramona, M.; Manson, E.; Kay, A.; Wiedenmann, B.; Laurent, D.; Cebon, J. Influence of hepatic dysfunction on safety, tolerability, and pharmacokinetics (PK) of PTK787/ZK222584 in patients with unresectable hepatocellular carcinoma. J. Clin. Oncol. 2005, 23, 4134.
205. Yau, T.; Chan, P.; Pang, R.; Ng, K.; Fan, S. T.; Poon, R. T. Phase 1-2 trial of PTK787/ZK222584 combined with intravenous doxorubicin for treatment of patients with advanced hepatocellular carcinoma. Cancer 2010, 116, 5022-5029.
206. Little, R. F.; Wyvill, K. M.; Pluda, J. M.; Welles, L; Marshall, V; Figg, W. D.; Newcomb, F. M.; Tosato, G.; Feigal, E.; Steinberg, S. M.; Whitby, D.; Goedert, J. J.; Yarchoan, R. Activity of thalidomide in AIDS-related Kaposi's sarcoma. J. Clin. Oncol. 2000, 18, 2593-2602.
207. Ang, S. F.; Tan, S. H.; Toh, H. C.; Poon, D. Y.; Ong, S. Y.; Foo, K. F.; Choo, S. P. Activity of thalidomide and capecitabine in patients with advanced hepatocellular carcinoma. Am. J. Clin. Oncol. 2012, 35, 222-227.
208. Laubach, J. P.; Schlossman, R. L.; Mitsiades, C. S.; Anderson, K. C.; Richardson, P. G. Thalidomide, lenalidomide and bortezomib in the management of newly diagnosed multiple myeloma. Expert Rev. Hematol. 2011, 4, 51-60.
209. Sun, P.; Zhang, L. M.; Sun, D. J.; Dong, L. L. Inhibitory effect of thalidomide on growth of human hepatoma cell line SMMC-7721 cells. Zhonghua Zhong Liu Za Zhi 2009, 31, 582-586.
210. Shiah, H. S.; Chao, Y.; Chen, L. T.; Yao, T. J.; Huang, J. D.; Chang, J. Y.; Chen, P. J.; Chuang, T. R.; Chin, Y. H.; Whang-Peng, J.; Liu, T. W. Phase I and pharmacokinetic study of oral thalidomide in patients with advanced hepatocellular carcinoma. Cancer Chemother. Pharmacol. 2006, 58, 654-664.
211. Hsu, C.; Chen, C. N.; Chen, L. T.; Wu, C. Y.; Hsieh, F. J.; Cheng, A. L. Effect of thalidomide in hepatocellular carcinoma: assessment with power Doppler US and analysis of circulating angiogenic factors. Radiology 2005, 235, 509-516.
212. Lin, A. Y.; Brophy, N.; Fisher, G. A.; So, S.; Biggs, C.; Yock, T. I.; Levitt, L. Phase II study of thalidomide in patients with unresectable hepatocellular carcinoma. Cancer 2004, 119-125.
213. Patt, Y. Z.; Hassan, M. M.; Lozano, R. D.; Nooka, A. K.; Schnirer, I. I.; Zeldis, J. B.; Abbruzzese, J. L.; Brown, T. D. Thalidomide in the treatment of patients with hepatocellular carcinoma. Cancer 2005, 103, 749-755.
214. Yau, T.; Chan, P.; Wong, H.; Ng, K. K.; Chok, S. H.; Cheung, T. T.; Lam, V.; Epstein, R. J.; Fan, S. T.; Poon, R. T. P. Efficacy and tolerability of low-dose thalidomide as first-line systemic treatment of patients with advanced hepatocellular carcinoma. Oncology 2007, 72, 67-71.
215. Pinter, M.; Winchlas, M.; Schmid, K.; Plank, C.; Müller, C.; Wrba, F.; Peck-Radosavljevic, M. Thalidomide in advanced hepatocellular carcinoma as antiangiogenic treatment approach: a phase I/II trial. Eur. J. Gastroenterol. Hepatol. 2008, 20, 1012-1019.
216. Ueda, H.; Tanaka, H.; Kida, Y.; Fukuchi, H.; Ichinose, M. Adjuvant chemotherapy with tegafur/uracil administration after transcatheter arterial chemoembolization for advanced hepatocellular carcinoma. Oncol. Reports 2008, 19, 1355-1361.
217. Shao, Y. Y.; Lin, Z. Z.; Hsu, C.; Shen, C. Y.; Hsu, C.C.; Cheng, A. L. Early alpha-fetoprotein response predicts treatment efficacy of antiangiogenic systemic efficacy of antiangiogenic systemic therapy in patients with advanced hepatocellular carcinoma. Cancer 2010, 116, 4590-4596.
218. Kanai, F.; Yoshida, H.; Tateishi, R.; Sato, S.; Kawabe, T.; Obi, S.; Kondo, Y.; Taniguchi, M.; Tagawa, K.; Ikeda, M.; Morizane, C.; Okusaka, T.; Arioka, H.; Shiina, S.; Omata, M. A phase I/II trial of the oral antiangiogenic agent TSU-68 in patients with advanced hepatocellular carcinoma. Cancer Chemother. Pharmacol. 2011, 67, 315-24.
219. Zhu, A. X.; Duda, D. G.; Sahani, D. V.; Jain, R. K. HCC and angiogenesis: possible targets and future directions. Nature Revs. Clin. Oncol. 2011, 8, 292-302.
220. Carmeliet, P.; Jain, R. K. Molecular mechanisms and clinical applications of angiogenesis. Nature 2011, 473, 298-307.
221. Reuben, S. C.; Gopalan, A.; Petit, D. M.; Bishayee, A. Modulation of angiogenesis by dietary phytoconstituents in the prevention and intervention of breast cancer. Mol. Nutr. Food Res. 2012, 56, 14-29.